ArticleCurrent medicinal chemistry2026
Single-Cell and Bulk Transcriptomic Integration Reveals a Stemness-Related Astrocyte Subpopulation for Prognostic Risk Stratification in Glioblastoma.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionGlioblastoma (GBM) is an aggressive brain tumor with pronounced heterogeneity. Stemness-related cell subpopulations are crucial for progression and therapy resistance, but their prognostic role remains unclear.
methodsWe integrated single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data to identify a stemness-high astrocyte subpopulation. Key genes were selected to construct a prognostic risk model using Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression, which was validated in The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) cohorts. Tumor microenvironment and pathway analyses were performed. in vitro functional assays were conducted on GBM cell lines.
resultsA four-gene signature (ALDOA, FABP5, TIMP1, and MT1M) was established. The risk model robustly stratified patients into high- and low-risk groups with distinct overall survival in both cohorts. Importantly, multivariate Cox regression confirmed the RiskScore as an independent prognostic factor beyond age and isocitrate dehydrogenase (IDH) mutation status. Functional validation revealed that ALDOA knockdown significantly suppressed GBM cell proliferation and migration in vitro. Further analyses showed that high-risk tumors were characterized by elevated immune/stromal scores, immunosuppressive cell infiltration, and activation of stemness-related pathways, including EGFR/MAPK, NF-αB, and VEGF-mediated angiogenesis. DISCUSSION: This integrated analysis identified a stemness-associated astrocyte subpopulation in GBM. The four-gene signature provides an independent prognostic tool and reflects immune microenvironment remodeling, offering insights into risk stratification and potential targeted therapy.
conclusionWe developed a stemness-associated four-gene signature that enables risk stratification in GBM and reveals an immunosuppressive microenvironment in high-risk tumors, providing new directions for prognosis and targeted therapy.
Indexed as
Identifiers
41944114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.